Navigation Links
Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA)
Date:3/3/2008

are expected during the second quarter of 2008. In Phase 1, PS433540 has been shown to be safe and well tolerated at a range of doses. The Phase 1 data also demonstrated that PS433540 produced statistically significant dose dependent increases versus placebo in plasma-renin activity levels as well as reductions in systolic and diastolic blood pressure in non- hypertensive healthy subjects.

PS433540 is a dual-acting angiotensin (AII) and endothelin (ET1) receptor antagonist that is being developed as a potential treatment for hypertension and diabetic nephropathy. PS433540, the first and only DARA compound in development, possesses two clinically validated mechanisms of action in a single compound. There is considerable preclinical and initial clinical data suggesting that compared to either agent alone, simultaneously blocking the actions of both AII and ET1 may provide significantly improved treatment options for several cardiovascular diseases.

ABOUT PHARMACOPEIA

Pharmacopeia is a clinical development stage biopharmaceutical company dedicated to discovering and developing novel small molecule therapeutics to address significant medical needs. The company has a broad portfolio of clinical and preclinical candidates under development internally or by partners including seven clinical compounds in Phase 2 or Phase 1 development addressing multiple indications including hypertension, diabetic nephropathy, muscle wasting, inflammation and respiratory disease. The company is leveraging its fully integrated drug discovery platform to sustain the growth of its development pipeline. Pharmacopeia has established strategic agreements with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Organon, Schering-Plough, and Wyeth Pharmaceuticals. For more information please visit the company's website at http://www.pharmacopeia.com.

'/>"/>
SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
2. Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
3. Pharmacopeia to Present at BIO CEO & Investor Conference 2008
4. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
5. Pharmacopeia Announces Third Quarter 2007 Financial Results
6. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
7. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
8. Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
11. Phosphagenics Initiates U.S. Clinical Trials for Its Topical Retinoic Acid
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... NEW YORK , July 29, 2014 /PRNewswire/ ... team of Caremark Rx, Drew Crawford today ... PBM365 is the leading independent media source dedicated to ... and opinion on the pharmacy benefit management (PBM) industry ... timely coverage of, and context behind, industry news.   The ...
(Date:7/29/2014)... July 29, 2014  Roche (SIX: RO, ROG; OTCQX: ... Clinical Chemistry (AACC) 2014 Clinical Lab Expo today by ... unique ways Roche is partnering with customers to redefine ... tell us every day that they,re looking for a ... in their labs and offices," said Jack Phillips ...
(Date:7/29/2014)... Laboratory (IL) today announced the launch of its new corporate ... of a comprehensive rebranding effort by Werfen, the parent company ... , in 1959, IL has been part of the ... the group include Inova Diagnostics ( San Diego, CA ... ).  Like IL, these three companies are focused on ...
Breaking Medicine Technology:Drew Crawford Announces Launch of PBM365 Media 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 4Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3
... 2007 -,Icagen, Inc. (NASDAQ: ICGN) today announced that ... at the C.E. Unterberg,Towbin Emerging Growth Opportunities Conference ... 2:00 p.m. ET., There will be a live ... will be accessible through a link posted on,the ...
... --,SuperGen, Inc. today announced that Dr. Gregory Berk, ... Towbin Emerging Growth,Opportunities Conference on Thursday, July 12, ... City. , SuperGen's presentation at the C.E. Unterberg, ... at 3:30 p.m.,EDT. A live webcast of the ...
Cached Medicine Technology:Icagen to Present at the C.E. Unterberg, Towbin Emerging Growth,Opportunities Conference 2SuperGen to Present at the C.E. Unterberg, Towbin Emerging Growth,Opportunities Conference 2
(Date:7/29/2014)... are chemical substances, which are able to kill unwanted ... prevent degradation of the physical and sensorial properties of ... used in various applications such as water treatment, personal ... It is also used in domestic applications such as ... to prevent fouling in water and oil pipelines. , ...
(Date:7/29/2014)... use of electronic medical records and health information ... computerized version of the preventive care guidelines pediatricians ... study, researchers from the Indiana University School of ... work lies ahead to convert the American Academy ... for physicians, but the payoff has the potential ...
(Date:7/29/2014)... 29, 2014 The Latin American poultry feed ... with analysis and forecast of revenue. The poultry feed and ... from $25,273.3 million and $647.2 million in 2013 to $34,024.0 ... 6.1% from 2013 to 2018, respectively. , To get an ... the TOC of the Latin American poultry feed and feed ...
(Date:7/29/2014)... HealthDay Reporter MONDAY, July 28, ... continues to rage throughout West Africa poses little risk to ... through physical touch, and it can,t be spread by people ... of the National Center for Emerging & Zoonotic Infectious Diseases ... in a Monday afternoon news conference. Those factors -- ...
(Date:7/29/2014)... including Penn State College of Medicine, have jointly ... a health data research network., The Patient-Centered Outcomes ... Patient Protection and Affordable Care Act, awarded the ... University and Johns Hopkins University -- and each ... have come together to create a Clinical Data ...
Breaking Medicine News(10 mins):Health News:North America Biocides Market is Expected to Reach 890.3 KT in 2016 - New Report by MicroMarket Monitor 2Health News:North America Biocides Market is Expected to Reach 890.3 KT in 2016 - New Report by MicroMarket Monitor 3Health News:North America Biocides Market is Expected to Reach 890.3 KT in 2016 - New Report by MicroMarket Monitor 4Health News:Study: Pediatric preventive care guidelines need retooling for computerized format 2Health News:Study: Pediatric preventive care guidelines need retooling for computerized format 3Health News:Latin America Poultry Feed Market is Expected to Reach $870.1 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Latin America Poultry Feed Market is Expected to Reach $870.1 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Latin America Poultry Feed Market is Expected to Reach $870.1 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Latin America Poultry Feed Market is Expected to Reach $870.1 Million in 2018 - New Report by MicroMarket Monitor 5Health News:CDC Downplays Ebola's Threat to the United States 2Health News:CDC Downplays Ebola's Threat to the United States 3Health News:CDC Downplays Ebola's Threat to the United States 4Health News:New network unites university health care research 2
... sickle cell disease who also have lower blood oxygen ... have heart abnormalities, researchers at Washington University School of ... Heart problems are fairly common in young adults ... why. The researchers demonstrated that lower oxygen saturation in ...
... ... (radial Keratotomy) may benifit from PRELEX with crystalens according to Dr. Khanna. , ... (Vocus) April 27, 2010 -- Patents that ... Khanna. Radial Keratotomy was in vogue in the late seventy’s and eighties. Its popularity declined ...
... function , TUESDAY, April 27 (HealthDay News) -- High-dose ... and patients on this regimen should stop immediately, says a ... believed it would show that high-dose vitamin B therapy (folic ... function and reduce their risk of heart attack and stroke. ...
... study finds problems contracting, relaxing, , TUESDAY, April 27 ... the heart more than had been thought, a new ... what might be the first clear evidence that these ... damage heart function, said Dr. Aaron L. Baggish, an ...
... Digestive Health and Nutrition (FDHN) announced this year,s recipient ... Kenneth P. Olive, PhD. The $225,000 gift from ... with funding and protected time for three years to ... Schwartz, a businessman and photographer, suffered from the disease ...
... ... to select their perfect retirement community based on community culture, personality, amenities and personal preferences. ... Princeton, NJ (PRWEB) ... can be a complicated, confusing chore. In fact, retirees and their families must choose ...
Cached Medicine News:Health News:Low blood oxygen may lead to heart defects in children with sickle cell disease 2Health News:Low blood oxygen may lead to heart defects in children with sickle cell disease 3Health News:Crystalens HD May Help People with RK 2Health News:Steroids Could Harm Heart's Pumping Ability 2Health News:Steroids Could Harm Heart's Pumping Ability 3Health News:Second AGA Foundation/Bernard Lee Schwartz Foundation Research Scholar Award presented 2Health News:RetiringbyDesign.com Offers Retirees a Smarter Way to Explore Living Options 2Health News:RetiringbyDesign.com Offers Retirees a Smarter Way to Explore Living Options 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: